Top San Francisco, California Biotech Companies (14)
Astellas Gene Therapies is an Astellas Center of Excellence developing genetic medicines with the potential to deliver transformative value for patients. Based on an innovative scientific approach and industry leading internal manufacturing capability and expertise, we are currently exploring three gene therapy modalities: gene replacement, exon skipping gene therapy, and vectorized RNA knockdown and will also advance additional Astellas gene therapy programs toward clinical investigation. We are based in San Francisco, with manufacturing and laboratory facilities in South San Francisco and Sanford, North Carolina.
MBC BioLabs helps life-science startups move faster, spend less, and achieve more. You rent only what you need and have access to millions of dollars in equipment (mass-spec, Biacore, FPLC, plate reader etc.) - allowing startups to begin reducing critical technical risks in their first week. And our endless supply of animal crackers and coffee, parties, and seminars make a great place to work!
Ascendco Health is an emerging health tech company that is devoted to empowering surgical teams with the tools and information they need to create a better work-life and ultimately deliver the highest levels of patient care. We believe that better data, better software, and better collaboration is the key to creating better habits and, most importantly, better care. Hospitals are filled with all sorts of amazing instruments that save resources, time, and lives. But when we look at the big picture we see something far more instrumental — you. The healthcare professionals that make everything go. With our platform every key stakeholder has the tools and information required for surgical excellence and superior patient care, 100% of the time.
DNA Script was created to revolutionize DNA synthesis with enzymes. Our core R&D efforts have produced innovations in enzyme engineering, surface and nucleotide chemistries, and instrumentation. The integration of these innovations has resulted in SYNTAX™️, the world’s first benchtop DNA printer powered by enzymatic technology. With continued advancement and innovation, we believe DNA Script’s enzymatic DNA synthesis technology is poised to become the engine of genomics research and personalized medicine
Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities (NCEs) that can potentially transform existing treatment paradigms in disease areas with significant unmet medical needs. Our platform enables us to discover peptides in a de novo fashion with the desired degree of potency, specificity and selectivity, and also engineer oral stability with specific peptidomimetic and chemical modifications.
.jpg)
We build enterprise cloud technology that powers the biggest names in life sciences (pharmaceutical/biotech). Our customers make vaccines, life-saving medicines, and life-enhancing products that make a difference in everyday lives. Our technology has transformed these industries; enabling them to get critical products and services to market faster.
TeselaGen's artificial Intelligence powered platform radically accelerates product development of therapeutics, high value chemicals, and agricultural products. We are located in the software hub of San Francisco, California.
Terremoto Biosciences is a covalent drug discovery and development engine creating highly targeted, small molecule medicines with unmatched selectivity, potency and efficacy. The company leverages the power of lysine-based covalency across the disease spectrum to develop both best-in-class therapies against known drug targets and first-in-class medicines against the previously undruggable. Many of Terremoto’s founders helped establish this emergent area of science, with the intent to broaden the number of tractable targets and deliver medicines with superior therapeutic benefit. Terremoto is supported by leading investors OrbiMed and Third Rock Ventures.
Rubedo Life Sciences is a biopharmaceutical company developing a broad portfolio of innovative therapies engineered to target cells which drive chronic age-related diseases. Our proprietary ALEMBIC™ drug discovery platform has engineered novel first-in-class small molecules designed to selectively target senescent cells, which play a key role in the progression of pulmonary, dermatological, oncological, neurodegenerative, fibrotic and other chronic disorders. The Rubedo leadership team is composed of industry leaders and pioneers in chemistry, technology, and the life sciences, with a deep bench of expertise in drug development and commercialization spanning from large pharma to biotech innovators. The company is based in Sunnyvale, CA.
We are building a new company to transform the cell therapy space by developing autologous cell therapies for patients with solid tumors. We are building a company culture based on collaboration, transparency, integrity, and commitment to excellence. We are looking for passionate people to be a part of this journey.
Maplight is a biopharmaceutical company discovering and developing novel therapeutics for patients with disorders of the central nervous system (CNS).
Specific Diagnostics' Impact on Sepsis With Sepsis, time is of the essence. Specific Diagnostic’s Reveal Rapid AST System produces AST results within an average of 5 hours directly from blood culture. This allows the patient’s care team to switch them to the optimal antibiotic therapy up to 2 days sooner than with traditional AST methods to ensure the bacterial infection is treated and doesn’t cause further harm.
Human Immunology Biosciences (HI-Bio) is leading clinical immunology into its next chapter with therapies that target cellular drivers of disease. HI-Bio uses a precision medicine approach to deliver therapies for patients with the auto-immune, allergic and inflammatory diseases that can together be referred to as immune-mediated diseases (IMDs).
Cytovale is a medical diagnostics company focused on providing a more rapid and insightful way to diagnose fast-moving and immune-mediated diseases. Our FDA cleared IntelliSep test is pioneering a new way of quickly and accurately analyzing white blood cells to stratify a patient’s risk of sepsis by performing a biomechanical evaluation of white blood cells collected from a standard blood draw in under 10 minutes. Cytovale’s first market application will be for sepsis, one of the fastest-moving, most lethal conditions in the world. Sepsis, a dysregulated immune response to infection, is often difficult to quickly and accurately diagnose. Sepsis is the no. 1 cause of death in hospitals, taking the lives of 270,000 people every year in the U.S. – more than opioid overdoses, prostate cancer, and breast cancer combined. Mortality from sepsis increases as much as eight percent with every hour of delayed treatment, and as much as 80 percent of sepsis deaths could be prevented with rapid diagnosis and treatment, making early detection essential. Cytovale aims to provide critical insight for early identification of patients at risk of having sepsis, in the time needed for it to be useful.
Work Your Passion. Live Your Purpose.
Industry
Work Your Passion. Live Your Purpose.
